Christine Berg

Q: What Schools Are Affiliated With Christine Berg

Christine Berg is affiliated with the following schools: Complutense University of Madrid, University of Oxford, Stanford University, Johns Hopkins University, University of Toronto, University of California, San Francisco, Harvard University

Christine Berg's AcademicInfluence.com Rankings

Christine Berg

Medical

#1625

World Rank

#1983

Historical Rank

#409

USA Rank

Oncology

#244

World Rank

#252

Historical Rank

#22

USA Rank

medical Degrees

Christine Berg

Philosophy

#10670

World Rank

#14641

Historical Rank

#1985

USA Rank

Logic

#7537

World Rank

#9324

Historical Rank

#1156

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Christine Berg's Degrees

Doctorate Medicine Harvard University
PhD Radiation Oncology Stanford University

Why Is Christine Berg Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Christine Dorothy Berg is an American radiation oncologist and physician-scientist who was chief of the early detection research group at the National Cancer Institute. Life Berg completed a M.D. at the Northwestern University School of Medicine. She completed a residency in internal medicine from 1977 to 1981 at the McGaw Medical Center. Berg conducted a fellowship in hematology and medical oncology from 1981 to 1984 at the National Institutes of Health Clinical Center. She was a resident in radiation oncology from 1984 to 1986 with MedStar Health.

(See a Problem?)

Christine Berg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Reduced lung-cancer mortality with low-dose computed tomographic screening. (2011) (6595)
Mortality results from a randomized prostate-cancer screening trial. (2009) (2824)
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer (2007) (1520)
The National Lung Screening Trial: overview and study design. (2011) (1043)
The decrease in breast-cancer incidence in 2003 in the United States. (2007) (949)
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. (2011) (942)
Probability of cancer in pulmonary nodules detected on first screening CT. (2013) (908)
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. (2012) (883)
Results of initial low-dose computed tomographic screening for lung cancer. (2013) (830)
Selection criteria for lung-cancer screening. (2013) (655)
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer (2009) (618)
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) (2009) (578)
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33 (2010) (542)
Detectable clonal mosaicism and its relationship to aging and cancer (2012) (512)
Targeting of low-dose CT screening according to the risk of lung-cancer death. (2013) (509)
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer (2015) (502)
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 (2009) (502)
Results of the two incidence screenings in the National Lung Screening Trial. (2013) (437)
Performance of common genetic variants in breast-cancer risk models. (2010) (430)
Genome-wide association studies identify four ER negative–specific breast cancer risk loci (2013) (411)
Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. (2011) (385)
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. (2011) (382)
Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force (2014) (379)
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer (2011) (306)
Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens (2011) (283)
Baseline Characteristics of Participants in the Randomized National Lung Screening Trial (2010) (280)
Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. (2011) (260)
Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. (2000) (257)
Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States. (2016) (250)
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3 (2011) (246)
Evaluation of the Lung Cancer Risks at Which to Screen Ever- and Never-Smokers: Screening Rules Applied to the PLCO and NLST Cohorts (2014) (244)
Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. (2016) (217)
Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. (2010) (206)
Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. (2007) (201)
Estrogen metabolism and risk of breast cancer in postmenopausal women. (2012) (191)
Second solid cancers after radiotherapy for breast cancer in SEER cancer registries (2009) (188)
Identification of Novel Genetic Markers of Breast Cancer Survival (2015) (185)
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. (2012) (182)
Impact of lung cancer screening results on smoking cessation. (2014) (169)
A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer (2011) (169)
Utilization of surveillance colonoscopy in community practice. (2010) (168)
Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. (2011) (167)
Serum Levels of Vitamin D Metabolites and Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (2008) (164)
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial (2008) (161)
Comorbidity and mortality results from a randomized prostate cancer screening trial. (2011) (161)
Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort (2009) (159)
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials (2017) (159)
Methods for etiologic and early marker investigations in the PLCO trial. (2005) (141)
Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST) (2011) (139)
Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. (2015) (133)
Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? (2012) (133)
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (2010) (132)
Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening (2009) (129)
IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3) (2008) (123)
A genome-wide association study identifies alleles in FGFR 2 associated with risk of sporadic postmenopausal breast cancer (2012) (122)
Serum Prostate-Specific Antigen Hemodilution Among Obese Men Undergoing Screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (2009) (120)
Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. (2010) (115)
Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis. (2011) (113)
Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening (2018) (107)
Vitamin D Receptor Polymorphisms and Breast Cancer Risk: Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (2009) (106)
Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. (2016) (98)
A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. (2012) (97)
Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. (2009) (96)
Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiation-induced cancer risk (2008) (89)
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. (2014) (88)
Measuring and Predicting Surgeons’ Practice Styles for Breast Cancer Treatment in Older Women (2001) (86)
Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. (2014) (76)
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. (2006) (70)
Genetic Variation in the HSD17B1 Gene and Risk of Prostate Cancer (2005) (69)
Eighteen Insulin-like Growth Factor Pathway Genes, Circulating Levels of IGF-I and Its Binding Protein, and Risk of Prostate and Breast Cancer (2010) (66)
Screening for lung cancer with low-dose computed tomography: a review of current status. (2013) (66)
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. (2013) (65)
Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. (2010) (59)
Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status (2012) (59)
Potential role of HE4 in multimodal screening for epithelial ovarian cancer. (2011) (56)
The efficacy of prostate‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials (2018) (55)
Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation (2016) (52)
The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. (2013) (52)
Experience with Reduction Mammaplasty following Breast Conservation Surgery and Radiation Therapy (1998) (50)
Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol (2019) (50)
Using Prediction-Models to Reduce Persistent Racial/Ethnic Disparities in Draft 2020 USPSTF Lung-Cancer Screening Guidelines. (2021) (45)
Patient and provider characteristics that affect the use of axillary dissection in older women with Stage I–II breast carcinoma (2002) (44)
Ovarian Cancer Screening in Women With a Family History of Breast or Ovarian Cancer (2006) (42)
Post-GWAS gene-environment interplay in breast cancer: results from the Breast and Prostate Cancer Cohort Consortium and a meta-analysis on 79,000 women. (2014) (41)
Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide association studies and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium. (2014) (41)
Factors associated with oxidative stress and cancer risk in the Breast and Prostate Cancer Cohort Consortium (2014) (40)
Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial (2013) (39)
Modeled Reductions in Late-stage Cancer with a Multi-Cancer Early Detection Test (2020) (39)
Life-GainedBased Versus Risk-Based Selection of Smokers for Lung Cancer Screening (2019) (38)
Body mass index and breast cancer survival: a Mendelian randomization analysis (2017) (38)
Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. (2012) (38)
The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma. (2012) (37)
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6 q 14 and 20 q 11 (2012) (36)
USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study (2021) (36)
Protocol and Rationale for the International Lung Screening Trial (2020) (35)
Sequence Variants of Estrogen Receptor β and Risk of Prostate Cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (2007) (35)
Prediction of True Positive Lung Cancers in Individuals with Abnormal Suspicious Chest Radiographs—A Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study (2009) (34)
Preventing Lung Cancer Mortality by Computed Tomography Screening: The Effect of Risk-Based Versus U.S. Preventive Services Task Force Eligibility Criteria, 20052015 (2018) (34)
Identification of candidates for longer lung cancer screening intervals following a negative low-dose computed tomography result. (2019) (34)
The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group. (2006) (25)
Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types (2015) (24)
Thyroid Cancer Rates and 131I Doses from Nevada Atmospheric Nuclear Bomb Tests: An Update (2010) (24)
Workshop on imaging science development for cancer prevention and preemption. (2006) (23)
Urinary biomarkers in radiation therapy of cancer. (1990) (22)
Preventing Lung Cancer Mortality by Computed Tomography Screening: The Effect of Risk-Based Versus U.S. Preventive Services Task Force Eligibility Criteria, 2005–2015 (2018) (22)
Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. (2015) (21)
Circulating Insulin-like Growth Factor (IGF)-I and IGF Binding Protein (IGFBP)-3 Levels and Postmenopausal Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort (2010) (20)
Vitamin D–Associated Genetic Variation and Risk of Breast Cancer in the Breast and Prostate Cancer Cohort Consortium (BPC3) (2014) (19)
PL02.02 Lung Cancer Screenee Selection by USPSTF Versus PLCOm2012 Criteria – Interim ILST Findings (2019) (19)
Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol. (2019) (18)
CT screening for lung cancer. (2007) (17)
Ovarian Volume: Determinants and Associations with Cancer among Postmenopausal Women (2006) (17)
Contemporary Implications of U.S. Preventive Services Task Force and Risk-Based Guidelines for Lung Cancer Screening Eligibility in the United States (2019) (17)
Radiation therapy and breast reconstruction. (1998) (17)
Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival. (2017) (16)
Cancer screening: the journey from epidemiology to policy. (2012) (16)
The National Lung Screening Trial's Endpoint Verification Process: determining the cause of death. (2011) (16)
Effect of screening on ovarian cancer mortality in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer randomized screening trial. (2011) (16)
Common colorectal cancer risk alleles contribute to the multiple colorectal adenoma phenotype, but do not influence colonic polyposis in FAP (2014) (15)
Genetic Variation on 9p22 Is Associated with Abnormal Ovarian Ultrasound Results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (2011) (14)
Brief Report: Insights for management of ground-glass opacities from the National Lung Screening Trial. (2019) (14)
Secondary chemoprevention of upper aerodigestive tract tumors. (2001) (14)
ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3) (2015) (14)
Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. (2015) (13)
Evaluation of Association of HNF 1 B Variants with Diverse Cancers : Collaborative Analysis of Data from 19 Genome-Wide Association Studies (2010) (12)
Lung cancer screening: promise and pitfalls. (2008) (10)
Formidable challenges ahead for lung cancer screening. (2012) (10)
Factors Associated with Human Small Aggressive Non–Small Cell Lung Cancer (2007) (10)
The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: The prostate cancer screening results in context (2011) (10)
Population Testing for High Penetrance Genes: Are We There Yet? (2018) (9)
Validation of Biomarker Panels for Ovarian Cancer A Framework for Evaluating Biomarkers for Early Detection : Updated (2011) (9)
Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. (2011) (9)
The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource (2016) (8)
Interactions Between Genome-Wide Significant Genetic Variants and Circulating Concentrations of 25-Hydroxyvitamin D in Relation to Prostate Cancer Risk in the National Cancer Institute BPC3 (2017) (8)
Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial. (2018) (8)
A Genome-Wide “Pleiotropy Scan” Does Not Identify New Susceptibility Loci for Estrogen Receptor Negative Breast Cancer (2014) (8)
Colorectal , and Ovarian Cancer Screening Trial Specimens Ovarian Cancer Biomarker Performance in Prostate , Lung , Updated (2011) (8)
Genetic Variation in the HSD 17 B 1 Gene and Risk of Prostate Cancer (2005) (8)
The chromosome 2 p 21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma (2012) (7)
Erratum: Radiographic imaging of bronchioloalveolar carcinoma: Screening, patterns of presentation and response assessment (Journal of Thoracic Oncology (2006) 1, (S20-S26)) (2007) (7)
Factors associated with inadequate colorectal cancer screening with flexible sigmoidoscopy. (2012) (7)
Interval lung cancers not detected on screening chest X-rays: How are they different? (2012) (7)
Who Is at Risk for Lung Cancer (2003) (6)
Data sharing in clinical trials: An experience with two large cancer screening trials (2017) (6)
Resolving the ductal carcinoma in situ treatment conundrum. (2013) (6)
Why Oncologists Should Care About Climate Change. (2020) (6)
Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) (2009) (6)
Computed tomography screening for lung cancer. (2007) (5)
The utility of conservative surgery and radiation therapy in ddctal carcinoma-in-situ (1993) (5)
Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies (2019) (5)
Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program (2022) (4)
Concerns and challenges in flexible sigmoidoscopy screening. (2012) (4)
Fine mapping of 14q24.1 breast cancer susceptibility locus (2012) (4)
Management of lung cancer screening results based on individual prediction of current and future lung cancer risk. (2021) (4)
DOES BMI IMPACT PSA CONCENTRATION BY VARIATION IN PLASMA VOLUME (2008) (3)
Eighteen Insulin-like Growth Factor (IGF) pathway genes, circulating levels of IGF-1 and its binding protein (IGFBP-3), and risk of prostate and breast cancer (2010) (3)
Lung cancer screening: promise and pitfalls. (2012) (3)
Lung adenocarcinoma promotion by air pollutants (2023) (3)
Improving uptake of cancer screening in women. (2007) (3)
An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial. (2021) (3)
Transitioning to Environmentally Sustainable, Climate-Smart Radiation Oncology Care. (2022) (2)
PROTOCOL FOR THE INTERNATIONAL LUNG SCREEN TRIAL (ILST): A COHORT STUDY TO DEFINE LDCT SCREENING SELECTION CRITERIA AND VALIDATE THE PANCAN NODULE MANAGEMENT ALGORITHM (2017) (2)
Prostate-Specific Antigen Screening for Prostate Cancer in Older Men in the United States of America (2012) (2)
Large field trial for lung cancer screening: putting the wrong cart before the horse? (2007) (2)
Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial (2019) (2)
Cumulative false-positives (FP) in the prostate, lung, colorectal, ovarian (PLCO) cancer screening trial (2007) (2)
Abstract IA18: Development and validation of risk models to select ever-smokers for CT lung-cancer screening (2017) (2)
1 Altered estrogen and antiestrogen responsivity in clonai, variants of MCF-7 human breast cancer cells (1983) (2)
Limitations of reduced‐field irradiated volume and technique in conventional radiation therapy of prostate cancer: Implications for conformal 3‐D treatment (2000) (2)
Dr. Andriole and colleagues reply (2009) (2)
Breast Cancer Risk FromModifiable and Nonmodifiable Risk Factors AmongWhiteWomen in the United States (2016) (2)
tilization of Surveillance Colonoscopy in Community Practice (1)
Climate Change and Oncology Nursing: A Call to Action. (2022) (1)
Tumor Gene Expression Profiles Can Guide Therapy Selection (2006) (1)
Factors Associated With Small Aggressive Non–Small Cell Lung Cancers in the National Lung Screening Trial: A Validation Study (2018) (1)
The reliability of the tuning fork and therapeutic ultrasound to determine the most reliable methods of fracture diagnosis (2009) (1)
Is Hysteroscopy an Accurate Diagnostic Tool (2002) (1)
Variation in the efficacy of low-dose computed tomographic lung screening based on risk of lung cancer mortality in the National Lung Screening Trial. (2013) (1)
Major changes in breast cancer incidence in the United States over the period 2002 to 2004 (2007) (1)
Breast Cancer Screening Interval: Risk Level May Matter (2016) (1)
333 FAMILY HISTORY OF VARIOUS CANCERS AND THE RISK OF INCIDENT PROSTATE CANCER IN THE PLCO TRIAL (2011) (1)
588 Effect of Flexible Sigmoidoscopy Screening on Incidence and Mortality From Colorectal Cancer in the PLCO Screening Trial (2012) (1)
993 FACTORS INFLUENCING INITIAL TREATMENT DECISIONS IN PLCO: COMPARISON OF SCREENING AND CONTROL ARMS (2012) (1)
PRE-BIOPSY PROSTATE CANCER NOMOGRAMS BASED UPON SERIAL PSA SCREENING DATA IN THE PLCO TRIAL WITH VERIFICATION BIAS CORRECTION (2009) (1)
An interprofessional experience exploring fashion design (2017) (1)
Tissue sampling and digital histologic imaging for the National Lung Screening Trial. (2010) (0)
Abstract 5291: Effect of screening CT results and features on lung cancer risk prediction within the National Lung Screening Trial (2017) (0)
INITIAL PSA LEVELS AND PROSTATE CANCER DIAGNOSIS WITH UP TO 7 YEARS FOLLOW-UP IN THE PLCO CANCER SCREENING TRIAL (2009) (0)
Fine mapping of 14q24.1 breast cancer susceptibility locus (2011) (0)
MA05.10 Performance of Draft 2020 USPSTF Lung-Cancer Screening Guidelines and Potential for use of Risk Models to Reduce Racial/Ethnic Disparities (2021) (0)
T1407: Factors Associated With Inadequate Colorectal Cancer Screening With Flexible Sigmoidoscopy (2010) (0)
Breast-Feeding: Does It Affect Breast Cancer Risk? (2002) (0)
l ung c ancer Screening in the r andomized Prostate, l ung, c olorectal, and Ovarian (P lc O) c ancer Screening t rial (2010) (0)
Screening in the randomized Prostate , lung , colorectal , and Ovarian ( PlcO ) cancer Screening trial (2010) (0)
P2.13-011 Optimal Selection Criteria for LDCT Lung Cancer Screening (2017) (0)
Mendelian Disorders of Membrane Trafficking (2011) (0)
A re-analysis of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial accounting for ovarian cancer (OVCA) heterogeneity. (2017) (0)
Just Say No! Smoking Abstinence Works. (2016) (0)
The Halstead Radical Mastectomy: Its Passing Should Not Be Mourned (2002) (0)
The Utility of Screening Mammography (2007) (0)
r esolving the ductal Carcinoma in Situ t reatment Conundrum (2013) (0)
FACTORS INFLUENCING METHOD OF INVESTIGATION OF AN ABNORMAL PSA IN THE PLCO TRIAL AND EFFECT ON CANCER DIAGNOSIS (2009) (0)
P1.11-36 A Simple Tool to Prioritize US Ever-Smokers for CT Screening Eligibility Assessment (2019) (0)
When Should Hormone Therapy Be Discontinued (2002) (0)
P1.04-003 The International Lung Screen Trial: A Multi-Center Study to Evaluate LDCT Screening Selection Criteria and Nodule Management (2017) (0)
Improving selection of individuals into lung cancer screening programmes. (2019) (0)
Research Activities #249, May 2001 (2001) (0)
Abstract 2232: Preliminary results for a novel single extracellular vesicle assay for early lung cancer: The power of co-localized detection of surface biomarkers (2022) (0)
Combined Therapy with Oophorectomy and Tamoxifen for Premenopausal Breast Cancer (2002) (0)
Women Who Provide Child Care Require Self-Care, Too (2004) (0)
CLINICAL—ALIMENTARY TRACT Utilization of Surveillance Colonoscopy in Community Practice (2010) (0)
PROSTATE CANCER RISK AND INITIAL TREATMENT DECISIONS IN THE PLCO CANCER SCREENING TRIAL (2008) (0)
Concerns and challenges in flexible sigmoidoscopy (2012) (0)
131 COMPARISON OF RISK ESTIMATES OF FACTORS ASSOCIATED WITH PROSTATE CANCER INCIDENCE AND MORTALITY BETWEEN SCREENED AND CONTROL ARMS IN THE PLCO TRIAL (2010) (0)
Potential for Using an Individualized Lung Cancer Risk Model to Suggest an Appropriate Screening Interval for Participants with Abnormal CT Screens (2020) (0)
Improving Research on Biomarkers for Early Detection and Screening of Cancers (2012) (0)
Lobular Neoplasia of the Breast: Should Our Concepts Be Changing? (2003) (0)
OP-JNCI190046 996..999 (2019) (0)
SCREENING :P ROMISE AND PITFALLS (2008) (0)
Developing Risk-Based Screening Guidelines: Translational Epidemiology in Action (2014) (0)
Adjuvant Therapy for Breast Cancer: Will Anastrozole Replace Tamoxifen? (2002) (0)
Abstract IA08: Individualized risk based lung cancer screening: The way forward (2018) (0)
DETERMINANTS OF RADICAL PROSTATECTOMY IN THE PROSTATE, LUNG, COLORECTAL, OVARIAN (PLCO) CANCER SCREENING TRIAL (2008) (0)
Continued Progress in Adjuvant Therapy for Breast Cancer (2004) (0)
OP-JNCI200215 1590..1594 (2021) (0)
Optimizing Radiation Therapy for Breast Cancer (2007) (0)
Gene-Expression Microarray Technology for Breast Cancer Prognosis? (2003) (0)
Beneﬁts and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force (2014) (0)
Risk of Prostate and Breast Cancer (2010) (0)
EFFECT OF OBESITY AT AGE 20 AND 50 ON DEVELOPMENT OF PROSTATE CANCER IN THE PLCO CANCER SCREENING TRIAL (2009) (0)
Unraveling the Molecular Genetics of Malignancy in Breast Cancer (2007) (0)
P2.11-07 Benefits and Harms of Contemporary Lung Cancer Screening: An Infographic to Support Public and Patient Education (2019) (0)
1159 PREDICTING THE RISK OF BLADDER CANCER AND HIGH-GRADE BLADDER CANCER USING PATIENT CLINICAL AND DEMOGRAPHIC INFORMATION FROM PLCO PARTICIPANTS (2010) (0)
Computed tomography screening for lung cancer. Authors' reply (2007) (0)
Clarifying the Biologic Underpinnings for Differences in Breast Cancer Survival (2006) (0)
Body mass index and breast cancer survival (2017) (0)
Optimizing Chemotherapy: The Importance of Estrogen-Receptor Status (2006) (0)
OA19.01 Prospective Study of Lung Cancer Screening Criteria: USPSTF2013 vs PLCOm2012 – International Lung Screening Trial (ILST) Results (2021) (0)
Improved Assessment of Cancer Risks in (2002) (0)
573 FACTORS INFLUENCING PROSTATE CANCER MORTALITY IN THE PLCO TRIAL (2010) (0)
Ovarian Cancer: Yet Another Reason Not to Smoke! (2002) (0)
Race-Ethnicity and Colorectal Cancer Disparities: Is There a Difference in Adenoma Initiation? Evidence from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (2009) (0)
Risk of Prostate Cancer–related Death Following a Low PSA Level in the PLCO Trial (2020) (0)
Lung cancer screening (2018) (0)
Lung cancer screening makes the GRADE. (2016) (0)
teen Insulin-like Growth Factor Pathway Genes , ulating Levels of IGF-I and Its Binding Protein , B & P Risk of Prostate and Breast Cancer (2010) (0)
Deciphering the Role of Genetic Testing for Cancer (2003) (0)
Abstract A110: Could use of individualized risk models mitigate health disparities in eligibility for lung cancer screening? (2020) (0)
Could Use of Individualized Risk Models Mitigate Health Disparities in Eligibility for Lung-Cancer Screening? (2020) (0)
Abstract 5298: Lung cancer risk and scarring on imaging and histology in the National Lung Screening Trial (2017) (0)
MA20.03 Surprising Implications of Proposed Risk-Thresholds for Selecting US Ever-Smokers into CT Lung-Cancer Screening (2018) (0)
Abstract PO-247: Use of prediction models to reduce racial/ethnic disparities in eligibility for lung-cancer screening (2020) (0)
Ovarian cancer screening and mortality - Reply (2011) (0)
Thiazide Use Decreases Hip Fracture Risk (2003) (0)
POTENTIAL FOR INCREASE IN SCREENING INTERVAL BASED ON INITIAL PSA: DATA FROM THE PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL (2009) (0)
Cancer prevention and screening (2018) (0)
Is Tailoring of Chemotherapy in (2006) (0)
Do Statins Lower Cholesterol and Prevent Breast Cancer (2006) (0)
PATTERN OF PSA CHANGE DURING SERIAL SCREENING IN THE PLCO CANCER SCREENING TRIAL AFFECTS PROSTATE CANCER RISK (2009) (0)

This paper list is powered by the following services:

Other Resources About Christine Berg

en.wikipedia.org

What Schools Are Affiliated With Christine Berg?

Christine Berg is affiliated with the following schools:

Christine Berg's Academic­Influence.com Rankings

Christine Berg's Degrees

Why Is Christine Berg Influential?

Christine Berg's Published Works

Published Works

Other Resources About Christine Berg

What Schools Are Affiliated With Christine Berg?

Christine Berg's AcademicInfluence.com Rankings